2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Adult
Apolipoproteins B
/ blood
Cardiovascular Diseases
/ prevention & control
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Dietary Supplements
Dyslipidemias
/ therapy
Eicosapentaenoic Acid
/ analogs & derivatives
Ezetimibe
/ therapeutic use
Female
Health Behavior
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
PCSK9 Inhibitors
/ therapeutic use
Pregnancy
Pregnancy Complications
Primary Prevention
/ standards
Risk Assessment
Secondary Prevention
/ standards
Journal
The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
12
03
2021
accepted:
16
03
2021
pubmed:
31
3
2021
medline:
21
12
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
The 2021 guidelines primary panel selected clinically relevant questions and produced updated recommendations, on the basis of important new findings that have emerged since the 2016 guidelines. In patients with clinical atherosclerosis, abdominal aortic aneurysm, most patients with diabetes or chronic kidney disease, and those with low-density lipoprotein cholesterol ≥ 5 mmol/L, statin therapy continues to be recommended. We have introduced the concept of lipid/lipoprotein treatment thresholds for intensifying lipid-lowering therapy with nonstatin agents, and have identified the secondary prevention patients who have been shown to derive the largest benefit from intensification of therapy with these agents. For all other patients, we emphasize risk assessment linked to lipid/lipoprotein evaluation to optimize clinical decision-making. Lipoprotein(a) measurement is now recommended once in a patient's lifetime, as part of initial lipid screening to assess cardiovascular risk. For any patient with triglycerides ˃ 1.5 mmol/L, either non-high-density lipoprotein cholesterol or apolipoprotein B are the preferred lipid parameter for screening, rather than low-density lipoprotein cholesterol. We provide updated recommendations regarding the role of coronary artery calcium scoring as a clinical decision tool to aid the decision to initiate statin therapy. There are new recommendations on the preventative care of women with hypertensive disorders of pregnancy. Health behaviour modification, including regular exercise and a heart-healthy diet, remain the cornerstone of cardiovascular disease prevention. These guidelines are intended to provide a platform for meaningful conversation and shared-decision making between patient and care provider, so that individual decisions can be made for risk screening, assessment, and treatment.
Identifiants
pubmed: 33781847
pii: S0828-282X(21)00165-3
doi: 10.1016/j.cjca.2021.03.016
pii:
doi:
Substances chimiques
Apolipoproteins B
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
PCSK9 Inhibitors
0
eicosapentaenoic acid ethyl ester
6GC8A4PAYH
Eicosapentaenoic Acid
AAN7QOV9EA
Ezetimibe
EOR26LQQ24
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
1129-1150Informations de copyright
Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.